Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00022308
- Locations
- 🇺🇸
Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
🇺🇸Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 18
- Registration Number
- NCT00006037
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005791
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00020917
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003867
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00004919
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00006786
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Cleveland, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00077298
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00077285
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
- Conditions
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 238
- Registration Number
- NCT00077233
- Locations
- 🇺🇸
Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.